RANI
Rani Therapeutics Holdings, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Rani Therapeutics Holdings, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Rani Therapeutics has 6 disclosed suppliers and 2 disclosed customers in SEC filings.
SentenceCelltrion will provide, and we will purchase, supply of ustekinumab biosimilar and adalimumab biosimilar at supply prices set forth in the respective Celltrion Agreement.
RANI 10-Kaccession 0001193125-26-126417
SentenceChugai is primarily responsible for preclinical development, manufacturing and supply of the Compound, and Rani is primarily responsible for seeking positive regulatory feedback related to the sterility of the microneedle used in the RaniPill, providing regulatory support to Chugai as needed, and performing Chemistry Manufacturing and Controls of the RaniPill.
RANI 10-Kaccession 0001193125-26-126417
SentenceChugai is primarily responsible for preclinical development, and for the manufacturing and supply of the Compound.
RANI 10-Kaccession 0001193125-26-126417
SentenceICL has agreed to exclusively license certain intellectual property to us for use solely within the Rani Field, but we may not obtain a license on favorable terms.
RANI 10-Kaccession 0001193125-26-126417
SentenceIn June 2021, we entered into an Amended and Restated Exclusive License Agreement with InCube Labs, LLC ("ICL"), which replaced the 2012 Exclusive License Agreement between ICL and Rani LLC, as amended in 2013, and terminated the 2012 Intellectual Property Agreement between ICL and Rani LLC, as amended in June 2013.
RANI 10-Kaccession 0001193125-26-126417
SentenceIn the case of PG-102 for RT-114, we obtain supply of drug substance from ProGen under the ProGen Collaboration Agreement.
RANI 10-Kaccession 0001193125-26-126417
SentenceChugai has primary responsibility for preclinical and clinical development, regulatory filings, and commercialization of the Chugai Product, while we are responsible for development of the device and for certain manufacturing and supply activities.
RANI 10-Kaccession 0001193125-26-126417
SentenceChugai paid us an up-front payment of $0.6 million upon execution of the Chugai Research Agreement.
RANI 10-Kaccession 0001193125-26-126417
Largest filed tie
—
Rani Therapeutics Holdings, Inc.
0.60
Expected move
No implied move.